Logo
x

Search

Subscribe Now

beigene

BeiGene Reports the US FDA approval for Tevimbra + CT as a 1L Treatment of Advanced ESCC

BeiGene Reports the US FDA approval for Tevimbra + CT as a 1L Treatment of Advanced ESCC

  • March 5, 2025
BeiGene’s Tevimbra Plus Chemotherapy Secures the US FDA’s Approval as a 1L Treatment of G/GEJ Cancers

BeiGene’s Tevimbra Plus Chemotherapy Secures the US FDA’s Approval as a 1L Treatment of G/GEJ Cancers

  • December 30, 2024
BeiGene and CSPC Pharmaceutical Collaborate to Develop SYH2039 for Solid Tumors

BeiGene and CSPC Pharmaceutical Collaborate to Develop SYH2039 for Solid Tumors

  • December 13, 2024
BeiGene’s (to be BeOne Medicines) Tevimbra Secures the EC’s Approval as a 1L Treatment of Esophageal Squamous Cell Carcinoma and G/GEJ Cancer

BeiGene’s (to be BeOne Medicines) Tevimbra Secures the EC’s Approval as a 1L Treatment of Esophageal Squamous Cell Carcinoma and G...

  • November 28, 2024
BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma

  • October 22, 2024
BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024

BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024

  • June 14, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.